Home Cart Sign in  
Chemical Structure| 84687-43-4 Chemical Structure| 84687-43-4

Structure of Astragaloside IV
CAS No.: 84687-43-4

Chemical Structure| 84687-43-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Astragaloside IV, an active component isolated fromAstragalus membranaceus, suppresses the activation ofERK1/2andJNK/b> , and downregulates matrix metalloproteases (MMP)-2, (MMP)-9in MDA-MB-231 breast cancer cells.

Synonyms: AS-IV; AST-IV

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Astragaloside IV

CAS No. :84687-43-4
Formula : C41H68O14
M.W : 784.97
SMILES Code : O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1O[C@@H]2[C@@]3([H])C(C)(C)[C@@H](O[C@H]4[C@@H]([C@H]([C@@H](CO4)O)O)O)CC[C@]3(C5)[C@]65CC[C@]7(C)[C@]([C@](C)(O8)CC[C@H]8C(C)(O)C)([H])[C@@H](O)C[C@](C)7[C@]6([H])C2
Synonyms :
AS-IV; AST-IV
MDL No. :MFCD16036240

Safety of Astragaloside IV

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • JNK

In Vitro:

Cell Line
Concentration Treated Time Description References
Astrocytes 1, 10, 50, 100, 200 μM 10 days AS-IV inhibited astrocyte replicative senescence, evidenced by decreased senescence-associated β-galactosidase activity and expression of senescence marker p16, increased nuclear level of lamin B1, and reduced pro-inflammatory senescence-associated secretory phenotype. PMC7137443
H9C2 cells 50 µM or 100 µM 24 hours AS-IV reversed the Dox-induced apoptosis and necrosis of H9C2 cells in a dose-dependent manner. PMC9276071
Caco-2 cells 150 µM 24 hours To evaluate the inhibitory effect of Astragaloside IV on LPS-induced inflammation in Caco-2 cells, the results showed that Astragaloside IV significantly reversed the inhibition of cell viability by LPS and reduced the production of inflammatory cytokines. PMC11061986
RGC-5 cells 100 mg/L 24 hours To investigate the protective effect of Astragaloside IV on H2O2-induced oxidative stress injury in RGC-5 cells, the results showed that Astragaloside IV increased cell survival rate, decreased apoptotic cell number, reduced H2O2-induced reactive oxygen species levels, inhibited the decrease of mitochondrial membrane potential, reduced cytochrome c release, inhibited Bax and caspase-3 expression, and increased Bcl-2 expression PMC6022471
Bone marrow-derived macrophages (BMDMs) 100 µM 24 hours AS-IV significantly suppressed pro-inflammatory macrophage subsets and promoted pro-resolving macrophage subsets. PMC8473681
mouse podocytes 10 µM, 20 µM, 40 µM 24 hours To evaluate the protective effects of Astragaloside IV on high glucose-induced podocyte injury, the results showed that Astragaloside IV significantly improved the expression levels of NLRP3, pro-caspase-1 and caspase-1, and inhibited the decrease in cell viability PMC8262660
BMSCs cells 0-80 μM 24, 48, 72 hours Astragaloside IV significantly enhanced the cell viability of BMSCs at 40 μM, while a further increase in concentration attenuated this effect. PMC8120474
RAW264.7 cells 10 μM, 40 μM, 80 μM 4 days Astragaloside IV promoted osteoclast differentiation at low concentrations (10 μM), while osteoclastogenesis was inhibited at higher concentrations with a reduction in the osteoclast area and accumulation of preosteoclasts. PMC8120474
THP-1 monocytes 80 nM 48 hours Astragaloside IV significantly inhibited IL-4 and IL-13-induced M2 polarization, as shown by reduced expression of CD206 and M2-associated genes. PMC6116548
A549 and H1299 lung cancer cells 80 nM 48 hours Astragaloside IV suppressed M2-CM-induced invasion, migration, and angiogenesis of A549 and H1299 cells. PMC6116548
Human bone marrow mesenchymal stem cells (BMSCs) 5 μM, 20 μM, 50 μM, 100 μM To evaluate the effect of AS-IV on BMSCs proliferation, results showed that AS-IV (50 μM) significantly increased BMSCs proliferation. PMC10623974
Human umbilical vein endothelial cells (HUVECs) 5 μM, 20 μM, 50 μM, 100 μM To evaluate the effect of AS-IV on HUVECs proliferation, migration, and tube formation ability, results showed that AS-IV (50 μM) significantly promoted HUVECs proliferation, migration, and tube formation ability. PMC10623974
TM3 cells 100 µM 3 days AS.IV effectively reduced mutant myocilin associated ER stress PMC8619727
A549 cells 100 μg/mL 48 hours To investigate the effect of Astragaloside IV on TGF-β1-induced epithelial-mesenchymal transition (EMT). Results showed that Astragaloside IV significantly reversed TGF-β1-induced EMT, inhibited α-SMA expression, and increased E-cadherin expression. PMC6111865

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J mice Lewis lung cancer model Intragastric administration 40 mg/kg Once daily for 21 days Astragaloside IV significantly inhibited the growth and metastasis of Lewis lung cancer and reduced the percentage of M2 macrophages in tumor tissue. PMC6116548
Wistar rats Dox-induced heart failure model intraperitoneal injection 1.0 mg/kg once daily for 9 weeks AS-IV treatment significantly increased the ejection fraction in heart failure rats, reduced cardiomyocyte apoptosis, and reversed the abnormal expression of DRP1 and mitofusin. PMC9276071
Mice MPTP-induced Parkinson's disease model Intraperitoneal injection 100 mg/kg Every 12 hours for 5 weeks AS-IV protected against the loss of dopamine neurons and behavioral deficits in the mouse model of PD, accompanied by reduced accumulation of senescent astrocytes in substantia nigra compacta. PMC7137443
SD rats Distraction osteogenesis model Intragastric administration 20 mg/kg/day Once daily for 4 weeks Astragaloside IV accelerated bone regeneration during DO by enhancing osteogenesis and preosteoclast-induced angiogenesis simultaneously, partially through AKT/GSK-3β/β-catenin signaling. PMC8120474
C57BL/6 mice DSS-induced colitis model Oral gavage 100 mg/kg Once daily for 10 days To evaluate the therapeutic effect of Astragaloside IV on DSS-induced colitis in mice, the results showed that Astragaloside IV significantly alleviated inflammation, improved intestinal barrier function, and acted by inhibiting the PI3K/AKT signaling pathway. PMC11061986
C57BL/6J mice DSS-induced colitis model Oral 50 or 100 mg/kg Once daily for 10 days AS-IV attenuated the inflammatory progression of DSS-induced colitis and promoted the phenotypic transition of macrophages from pro-inflammatory to pro-resolving macrophages. PMC8473681
Sprague-Dawley rats Glucocorticoid-induced avascular necrosis of the femoral head model Oral gavage 20 mg/kg/day Once daily for 6 weeks To evaluate the protective effect of AS-IV on glucocorticoid-induced avascular necrosis of the femoral head, results showed that AS-IV promoted osteogenesis and angiogenesis via the Akt/Runx2 and Akt/HIF-1α/VEGF pathways, respectively, and suppressed apoptosis and oxidative stress via the Akt/Bad/Bcl-2 and Akt/Nrf2/HO-1 pathways, respectively. PMC10623974
Mice db/db mice intragastric administration 40 mg/kg once daily for 12 weeks To evaluate the protective effects of Astragaloside IV on diabetic nephropathy in db/db mice, the results showed that Astragaloside IV significantly reduced weight gain, hyperglycemia and serum triglyceride levels, improved renal function and podocyte injury, and inhibited NLRP3 inflammasome-mediated inflammation PMC8262660
Kunming mice Acute alcohol-induced liver injury model Oral 50, 150, and 500 mg/kg Once daily for 7 days Astragaloside IV ameliorates acute alcohol-induced liver injury by modulating gut microbiota and inhibiting NLRP3/Caspase-1 signaling pathway. PMC10228327

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01553643 Intracranial Arterial Stenosis Phase 4 Unknown - Taiwan ... More >> China Medical University Hospital Recruiting Taiching, Taiwan Contact: Chung Hsiang Liu, MD. Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.27mL

0.25mL

0.13mL

6.37mL

1.27mL

0.64mL

12.74mL

2.55mL

1.27mL

References

 

Historical Records

Categories